Medpage Today on MSN14h
Study Questions Need to Hold SGLT2 Inhibitors Before SurgeryPreoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...
Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...
An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...
Consultant in endocrinology and diabetes Professor Vinod Patel discusses current recommended pharmacological treatment ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...
A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...
A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...
The Brighterside of News on MSN2h
First of its kind drug significantly reduces heart attacks and strokesA recently approved drug has shown promise in reducing heart attacks and strokes in patients with type 2 diabetes and kidney disease. This medication, a sodium-glucose cotransporter (SGLT) inhibitor, ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback